IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Immuron Ltd
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026
$0.96−0.03 (-2.62%)
Close on Oct 19, 2026
Immuron Ltd revenue by segment
By business segment
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyper-Immune Products [Member] | A$1.55M | A$1.34M | A$1.35M | A$878.60K | -A$32.54K | -A$928.26K | A$968.72K | A$843.06K | A$573.94K | A$384.70K | +15.5% |
| Research and Development [Member] | -A$811.31K | -A$2.78M | -A$2.47M | -A$500.58K | A$275.43K | -A$936.02K | -A$870.46K | -A$513.52K | -A$408.10K | -A$3.03M | -70.8% |
| Corporate [Member] | -A$4.59M | -A$3.91M | -A$4.68M | -A$3.95M | -A$3.11M | -A$6.52M | – | – | – | – | +17.5% |
| Unallocated [Member] | – | – | – | – | – | – | -A$3.00M | -A$4.99M | -A$3.51M | -A$4.08M | – |
| Other [Member] | – | – | – | – | -A$3.11M | -A$6.52M | -A$3.00M | -A$4.99M | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Immuron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.